

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for treating an infection in an animal, said composition comprising:
 - (a) antimicrobial compound; and
 - (b) a pharmaceutically acceptable carrier for parenteral administration.
2. The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises an organic phenolic compound.
3. The pharmaceutical composition of claim 2 wherein the organic phenolic compound is reacted with a Group I salt.
4. The pharmaceutical composition of claim 2 wherein the organic phenolic compound is selected from isopropyl-o-cresol, isopropyl-cresol and combinations thereof.
5. The pharmaceutical composition of claim 3 wherein the Group I base is a Group I hydroxide base.
6. The pharmaceutical composition of claim 5 wherein the Group I base is selected from sodium hydroxide, potassium hydroxide and combinations thereof.
7. The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises isopropyl-o-cresol and isopropyl-cresol chemically reacted with sodium hydroxide and potassium hydroxide.
8. The pharmaceutical composition of claim 1 comprising from 0.1wt% to 15wt% antimicrobial compound

9. The pharmaceutical composition of claim 1 comprising from 0.1wt% to 15wt% antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous, intradermal, or intramuscular administration.

10. The pharmaceutical composition of claim 1 comprising from 3.5% to 10% antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises a vegetable oil.

11. The pharmaceutical composition of claim 10 wherein the pharmaceutically acceptable carrier comprises olive oil.

12. The pharmaceutical composition of claim 1 comprising from 0.1wt% to 1.0wt% antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.

13. The pharmaceutical composition of claim 12 comprising from 0.5% to 0.8% antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises 0.5wt% to 1.0wt% sodium chloride.

14. The pharmaceutical composition of claim 4 wherein the antimicrobial compound comprises more isopropyl-o-cresol than isopropyl cresol.

15. The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises between 55wt% and 99wt% isopropyl-o-cresol or base reacted isopropyl-o-cresol and between 1wt% and 45wt% isopropyl cresol or base reacted isopropyl cresol.

16. The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises between 75wt% and 99wt% isopropyl-o-cresol or base reacted

isopropyl-o-cresol and between 1wt% and 25wt% isopropyl cresol or base reacted isopropyl cresol.

17. The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises between 90wt% and 99wt% isopropyl-o-cresol or base reacted isopropyl-o-cresol and between 1wt% and 10wt% isopropyl cresol or base reacted isopropyl cresol.

18. The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises between 95wt% and 99wt% isopropyl-o-cresol or base reacted isopropyl-o-cresol and between 1wt% and 5wt% isopropyl cresol or base reacted isopropyl cresol.

19. The pharmaceutical composition of claim 1 wherein the animal is selected from humans, horses, cows, pigs, sheep, goats, rabbits, dogs, cats, chickens, turkeys, ducks and birds.

20. The pharmaceutical composition of claim 1 wherein the infection comprises infection by *E. coli*, *Salmonella* spp., *Pasteurella* spp., *Staphylococcus* spp., *Streptococcus* spp., *Corynebacterium* spp., *Bacillus* spp., *Clostridium* spp., *Sphaerotilus* spp., *Candida* spp., *Trychophyton* spp., *Microsporum* spp., *Micobacterium* spp., *Cryptosporidia* spp., *Microsporidia* spp., *Listeria monocytogenes*, *Lawsonia intracellularis*, *Treponema desynteriae*, *Enterococcus* spp., *Haemophilus* spp., *Campylobacter* spp., *Chlamydia*, *Brucella* spp., or *Vibrio* spp.

21. A method for treating infection in an animal, said method comprising:
administering to the animal a pharmaceutical composition comprising antimicrobial compound and a pharmaceutically acceptable carrier for parenteral administration.

22. The method of claim 21, wherein said antimicrobial compound comprises an organic phenolic compound.

23. The method of claim 22, wherein the organic phenolic compound is reacted with a Group I base.

24. The method of claim 23, wherein the organic phenolic compound is selected from isopropyl-o-cresol, isopropyl-cresol and combinations thereof.

25. The method of claim 23 wherein the Group I base is a Group I hydroxide base.

26. The method of claim 25 wherein the Group I base is selected from sodium hydroxide, potassium hydroxide and combinations thereof.

27. The method of claim 21 wherein the antimicrobial compound comprises isopropyl-o-cresol and isopropyl-cresol chemically reacted with sodium hydroxide and potassium hydroxide.

28. The method of claim 21 wherein the animal is selected from the group consisting of humans, horses, cows, pigs, sheep, goats, rabbits, dogs, cats, chickens, turkeys, ducks and birds.

29. The method of claim 21 wherein the infection comprises infection by *E. coli*, *Salmonella* spp., *Pasteurella* spp., *Staphylococcus* spp., *Streptococcus* spp., *Corinebacterium* spp., *Bacillus* spp., *Clostridium* spp., *Spherothorax* spp., *Candida* spp., *Trychophyton* spp., *Microsporum* spp., *Micobacterium* spp., or *Vibrio* spp.

30. The method of claim 21 wherein the infection comprises an internal infection.

31. The method of claim 30, comprising an infection of lungs, kidneys, joints, throat, muscles, or organs.
32. The method of claim 31, comprising an infection of tonsils.
33. The method of claim 21 wherein the infection comprises an external infection.
34. The method of claim 33 wherein the external infection comprises dermatitis or boils.
35. The method of claim 21, wherein said animal is a human animal.
36. Specific independent claim for VBG in composition.